Tuesday, December 05, 2006 6:30:00 AM PDT | VentureDeal Staff
MD -- Cylex, a medical testing company, announced
that it has obtained $18.4 in third round funding, bringing its total funding
to $30.8 million.
The company's FDA-approved flagship product is a test that measures the health
and vitality of a person's immune system from a drop of blood. The test
can tell physicians if a person is healthy enough to withstand treatments that
are harsh on the body, such as chemotherapy.
Channel Medical Partners and Canaan Partners led the round and each assumed one
board of directors seat.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.